NCT06105294

Brief Summary

This is a pilot trial to examine the acceptability and feasibility of time-restricted eating as an adjunct to medication treatment for bipolar disorder.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2023

Completed
4 months until next milestone

Study Start

First participant enrolled

June 1, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 27, 2023

Completed
Last Updated

October 27, 2023

Status Verified

October 1, 2023

Enrollment Period

2 months

First QC Date

February 6, 2023

Last Update Submit

October 23, 2023

Conditions

Keywords

eatingcircadian

Outcome Measures

Primary Outcomes (2)

  • Acceptability as assessed using self-ratings on items designed for this study

    self-ratings of the acceptability of the intervention

    Immediately post-treatment (10 weeks)

  • Feasibility as assessed by percent of clients who complete the assessments and intervention

    Percentage of clients who do not drop out of the trial. Drop out would be defined as not completing the TRE intervention, or failing to complete the end-of-treatment intervention.

    Immediately post-treatment (10 weeks)

Secondary Outcomes (4)

  • Lower Mania symptoms as assessed with the Patient Mania Questionnaire-9

    Change from baseline to immediately post-treatment (10 weeks)

  • Lower Depression symptoms as assessed with the Patient Health Questionnaire-9

    Change from baseline to immediately post-treatment (10 weeks)

  • Lower scores on two Patient Reported Outcome Measurement Information System (PROMIS) sleep scales

    Change from baseline to immediately post-treatment (10 weeks)

  • higher scores on Self-rated Quality of Life

    Change from baseline to immediatly post-treatment (10 weeks)

Other Outcomes (1)

  • Higher Functional impairment on the World Health Organization Disability Assessment Schedule (WHO-DAS2.0)

    Change from baseline to immediatly post-treatment (10 weeks)

Study Arms (1)

time-restricted eating

EXPERIMENTAL

Post-baseline, participants will be asked to restrict their eating to a 10-hour window.

Behavioral: time-restricted eating

Interventions

Restrict eating to a 10-hour window.

time-restricted eating

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adults diagnosed with bipolar disorder and currently receiving medical care for their bipolar disorder.
  • Experiencing schedule/sleep or circadian problem in the past 3 months
  • Medication regimens stable for past month
  • Adequate English language skills for taking part in the program.
  • Living in California.

You may not qualify if:

  • Cognitive deficits (Screening OMC Test)
  • Current: psychosis, (hypo)mania, major depressive episode, substance/alcohol use disorders, eating disorder diagnoses or acute suicidal risk (MINI interview; see DSM5 TRE screening)
  • High scores (\> 5) on the Screening Eating Disorder Examination Questionnaire
  • Current shift work
  • \>5 kg weight change within 3 months
  • Pregnancy
  • Breastfeeding
  • Uncorrected hypo or hyperthyroidism
  • \* diabetes type 1
  • Gastrointestinal conditions impairing nutrient absorption
  • Medications contraindicated for fasting, including clozapine, glucose-lowering medications, diabetes-related injections, requiring food early morning or late evening, corticosteroids.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California

Berkeley, California, 94720, United States

Location

Related Links

MeSH Terms

Conditions

Bipolar Disorder

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Participants will take part in a baseline assessment, then all will be assigned to time-restricted eating.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2023

First Posted

October 27, 2023

Study Start

June 1, 2023

Primary Completion

July 31, 2023

Study Completion

July 31, 2023

Last Updated

October 27, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will share

De-identified data will be available at OSF post-study.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Within one year of study completion, if ethics board approves.
Access Criteria
Available through OSF.

Locations